OncLive TV

Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.

Jerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.

Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

Nicole O. Williams, MD, discusses treatment considerations for selecting between CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the clinical implications of the phase 3 PRIMA trial in newly diagnosed advanced ovarian cancer.

Ezra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.

Philippe Moreau, MD, discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

Dickran G. Kazandjian, MD, discusses the rationale to evaluate retreatment with BCMA-directed therapy in multiple myeloma.

Luciano J. Costa, MD, PhD, discusses the rationale to develop later-line therapies for use in the frontline setting in multiple myeloma.

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Michael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Suthee Rapisuwon, MD, discusses the utility of frontline immunotherapy vs targeted therapy in acral and mucosal melanoma.

Eirwen M. Miller, MD, discusses the potential utility of sequential PARP inhibition in ovarian cancer.

Nisha A. Mohindra, MD, discusses the impact of the FDA approval of lurbinectedin in the treatment of patients with small cell lung cancer.

Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.

Dan J. Raz, MAS, MD, discusses the effects of COVID-19 on lung cancer screening.

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

Ashutosh K. Tewari, MD, discusses some of the key differences between racial subgroups in prostate cancer.

Olwen Hahn, MD, discusses future research directions with tucatinib (Tukysa) in the treatment of patients with breast cancer.

Ashutosh K. Tewari, MD, discusses the hallmarks of cancer among Black men with prostate cancer.

Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

Alan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.

Ashutosh K. Tewari, MD, director, Department of Urology, Mount Sinai, discusses the potential benefits of a mobile MRI unit in prostate cancer.

Lewis Au, MBBS, BMedSci, FRACP, discusses the results of a subgroup analysis evaluating antibody responses to COVID-19 in patients with cancer.